As of Thursday close, Hims & Hers Health Inc.’s (NYSE:HIMS) stock was down -$0.18, moving down -2.15 percent to $8.20. The average number of shares traded per day over the past five days has been 2,489,680 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.21 fall in that time frame. In the last twenty days, the average volume was 2,792,155, while in the previous 50 days, it was 2,852,786.
Since last month, HIMS stock retreated -7.76%. Shares of the company fell to $8.08 on 07/25/23, the lowest level in the past month. A 52-week high of $12.34 was reached on 05/08/23 after having rallying from a 52-week low of $4.01. Since the beginning of this year, HIMS’s stock price has risen by 27.93% or $1.79, and marked a new high 23 times. However, the stock has declined by -33.55% since its 52-week high.
HIMS stock investors should be aware that Hims & Hers Health Inc. (HIMS) stock had its last reported insider trading activity 16 days ago on Jul 19. Dudum Andrew, the Chief Executive Officer of the company, disposed of 23,800 shares for $9.06 on Jul 19. It resulted in a $215,607 divestment by the insider. Dudum Andrew sold 64,469 shares at an average price of $9.13 on Jul 18. The insider now owns 0 shares following the transaction. On Jul 06, Chief Operating Officer Baird Melissa sold 9,133 shares at $8.68 apiece. The transaction was valued at $79,283.
Valuation Metrics
The stock’s beta is 0.49. Besides these, the trailing price-to-sales (P/S) ratio of 2.71, the price-to-book (PB) ratio of 5.43.
Financial Health
In the three months ended March 30, Hims & Hers Health Inc.’s quick ratio stood at 3.60, while its current ratio was 4.00, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 79.10% percent. In the year ended March 30, EBITDA margin amounted to -11.58%, whereas operating margins totaled -10.20%. Based on annual data, HIMS earned $408.72 million in gross profit and brought in $526.92 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -22.00%. Return on equity (ROE) for the past 12 months was -19.00%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. HIMS’s revenue rose 46.89% to $167.2 million during the quarter, while net income inched up to $190.77 million. While analysts expected Hims & Hers Health Inc. to report -$0.07 quarterly earnings, the actual figure was -$0.05 per share, beating the consensus estimate by 28.60%. During the quarter, the company generated -$10.19 million in EBITDA. The liabilities of Hims & Hers Health Inc. were 63.56 million at the end of its most recent quarter ended March 30, and its total debt was $4.9 million. The value of shareholders’ equity is $209.32 million.
Technical Picture
This quick technical analysis looks at Hims & Hers Health Inc.’s (HIMS) price momentum. With a historical volatility rate of 39.56%, the RSI 9-day stood at 39.15% on 03 August.
With respect to its five-day moving average, the current Hims & Hers Health Inc. price is down by -2.50% percent or -$0.21. At present, HIMS shares trade -5.20% below its 20-day simple moving average and -8.58% percent below its 100-day simple moving average. However, the stock is currently trading approximately -13.68% below its SMA50 and +71.91% above its SMA200.
Stochastic coefficient K was 29.57% and Stochastic coefficient D was 45.70%, while ATR was 0.37. Given the Stochastic reading of 9.68% for the 14-day period, the RSI (14) reading has been calculated as 41.58%. As of today, the MACD Oscillator reading stands at -0.03, while the 14-day reading stands at -0.12.
Analyst Ratings
TD Cowen launched its rating on Hims & Hers Health Inc. (NYSE: HIMS) to an Outperform in a note to investors on July 28, 2023. Hims & Hers Health Inc. (HIMS) has been rated Overweight by analysts. According to 0 brokerage firms, HIMS is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Hims & Hers Health Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $12.50, the current consensus forecast for the stock is $10.00 – $18.00. Based on these forecasts, analysts predict Hims & Hers Health Inc. (HIMS) will achieve an average price target of $12.90.
